




CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Oversight Committee Meeting

July 31, 2020





Oversight Committee Meeting Agenda

July 31, 2020
9:00 a.m.

This Meeting Will Be Conducted by Videoconference and Telephonically

In accordance with Texas Government Code Section 418.016 Governor Abbott has suspended various provisions that require government officials and members of the public to be physically present at a specified meeting location.

Members of the public may connect to the meeting by going to the URL <https://zoom.us/j/99146900342?pwd=S3ZINW1qNVN6VjgySTZWZ1NxVmdnZz09>

The public may also join via telephone audio only using the following:

US: +1 346 248 7799 or +1 253 215 8782 or +1 669 900 9128 and entering the Webinar ID of 991 4690 0342 when prompted.

In the event technical issues occur, the agency will resume the meeting using a backup conference bridge line that will be available by calling 1-877-820-7831, participant passcode 340538. CPRIT will post the agenda packet by July 29 and a meeting recording after the meeting on CPRIT's public website (<https://cprit.texas.gov/oversight-committee/meetings/>).

A member of the public wishing to comment during the meeting must contact Melanie Cleveland (mcleveland@cprit.texas.gov) at least 30 minutes in advance of the posted meeting start time. When the Oversight Committee reaches the "Public Comment" agenda item, the Chair will recognize by name each person requesting to provide public comment. The Chair may limit the amount of time a member of the public may speak. CPRIT cannot guarantee that anyone contacting Ms. Cleveland less than 30 minutes before the posted start may provide comment.

The Oversight Committee may discuss or act on any item on this agenda, and as authorized by the Texas Open Meetings Act, Texas Government Code Section 551.001 et seq., may meet in closed session concerning any purpose permitted by the Act.

1. Call to Order
2. Roll Call/Excused Absences
3. Public Comment
4. Legislative Appropriations Request for the 2022-23 Biennium Tab 1
5. Academic Research Program Tab 2
 - FY 2021 Requests for Applications and Timeline
6. Product Development Research Program Tab 3
 - FY 2021 Requests for Applications and Timeline
 - RP110508, DP160057
7. Prevention Program Tab 4
 - FY 2021 Requests for Applications and Timeline

8. FY 2022 Program Priorities and CPRIT 2.0 Planning Tab 5
9. Compliance Investigation Pursuant to Health & Safety Code § 102.2631
10. Consultation with General Counsel
11. Future Meeting Dates and Agenda Items Tab 6
12. Adjourn



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

[Tab 1,
Return to Agenda](#)

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: HEIDI MCCONNELL, CHIEF OPERATING OFFICER
SUBJECT: LEGISLATIVE APPROPRIATIONS REQUEST FOR THE
2022-23 BIENNIUM
DATE: JULY 23, 2020

For the 2022-23 biennium, CPRIT staff have developed a budget request that includes:

- 1) \$300 million in general obligation bonds for each year of the 2022-23 biennium, or \$600 million for the biennium;
- 2) An exceptional item to maintain level funding for on-going increased costs for peer review honoraria, product development grant application due diligence, grant revenue asset management, and outsourced pre- and post-award grant management services through a budget adjustment of \$2.7 million to the budget strategy for grant review and award operations, reducing the amount available for research and prevention awards by the same amount;
- 3) An exceptional item for eight (8) additional full-time equivalent (FTE) positions for additional grant compliance, accounting, and program workload totaling \$611,117 and \$593,629 in each year of the biennium inclusive of salaries, one-time computer equipment costs, annual software subscription charges, and annual mobile phone and data card utility costs;
- 4) A modification to Rider 4, Transfer Authority, to allow CPRIT to submit notification to the Legislative Budget Board of budget transfers between budget line items under the general 20% transferability among budget line items allowed all state agencies versus submitting a request for approval of a budget transfer as currently required of only CPRIT; and
- 5) A 10% increase to the Chief Scientific Officer exempt salary cap from \$553,500 to \$608,850.

CPRIT Legislative Appropriations Request for the 2022-23 Biennium

Budget Strategies	FY 2019 Expended	FY 2020 Budgeted	FY 2021 Budgeted	FY 2022 Requested	FY 2023 Requested	FY 2022 Requested Adjusted for Exceptional Items	FY 2023 Requested Adjusted for Exceptional Items
A.1.1. Award Cancer Research Grants	\$ 251,780,707	\$ 249,116,755	\$ 251,620,104	\$ 251,620,104	\$ 251,620,104	\$ 248,398,420	\$ 248,414,159
<i>Lapsed Research Grant Appropriations Authority</i>	\$ (42,530,397)						
A.1.2. Award Cancer Prevention Grants	\$ 28,054,907	\$ 28,070,076	\$ 28,050,081	\$ 28,050,081	\$ 28,050,081	\$ 27,961,272	\$ 27,963,021
<i>Lapsed Prevention Grant Appropriations Authority</i>	\$ (1,196,513)						
A.1.3. Grant Review and Award Operations	\$ 14,284,984	\$ 15,918,209	\$ 12,886,730	\$ 12,886,730	\$ 12,886,730	\$ 16,167,223	\$ 16,149,735
B.1.1. Indirect Administration	\$ 3,754,717	\$ 4,548,878	\$ 4,380,053	\$ 4,380,053	\$ 4,380,053	\$ 4,410,053	\$ 4,410,053
<i>Lapsed Administrative Budget Appropriations (Unexpended Service Contracts)</i>	\$ (799,879)						
<i>Administrative Budget Appropriations Unexpended Balance Carryforward (Service Contracts)</i>	\$ (694,004)						
<i>Unrealized License Plate Revenue</i>	\$ (5,249)						
<i>License Plate Receipt Revenue Unexpended Balance Carryforward</i>	\$ (20,633)						
TOTAL BUDGET EXPENDITURES/ APPROPRIATION	\$ 252,628,640	\$ 297,653,918	\$ 296,936,968	\$ 296,936,968	\$ 296,936,968	\$ 296,936,968	\$ 296,936,968

Rider 5 Transfer to DSHS for the Cancer Registry	\$	2,969,554	\$	3,118,032	\$	3,118,032	\$	3,118,032	\$	3,118,032	\$	3,118,032	\$	3,118,032
--	----	-----------	----	-----------	----	-----------	----	-----------	----	-----------	----	-----------	----	-----------

Method of Finance								
780 G.O. Bond Proceeds	\$	252,556,690	\$	297,575,972	\$	296,881,968	\$	296,881,968
666 Appropriated Receipts	\$	71,950	\$	40,000	\$	40,000	\$	40,000
802 License Plate Trust Fund Account	\$	-	\$	34,995	\$	15,000	\$	15,000
Total Method of Finance	\$	252,628,640	\$	297,650,967	\$	296,936,968	\$	296,936,968

Unbudgeted ERS Transfer for DSHS Retired Employee Insurance Payments	\$	(389,362)	\$	(506,282)	\$	(506,282)	\$	(506,282)	\$	(506,282)
--	----	-----------	----	-----------	----	-----------	----	-----------	----	-----------

CPRIT Legislative Appropriations Request for the 2022-23 Biennium

Exceptional Item Request 1
Item Name: Maintain Level Funding for Grant Review and Award Operations

Description/Justification:	Funding for the Following Strategies	Exceptional 2022	Exceptional 2023
CPRIT requires an adjustment to address an annual appropriation shortfall for on-going grant review and award operating costs including Review Council honoraria, grant revenue asset management with the Texas Safekeeping Trust Company, product development grant application due diligence, and outsourced pre- and post-award grant management support costs.	A.1.1. Award Cancer Research Grants	\$ (2,429,438)	\$ (2,429,438)
	A.1.2. Award Cancer Prevention Grants	\$ (269,938)	\$ (269,938)
	A.1.3. Grant Review and Award Operations	\$ 2,699,376	\$ 2,699,376
	Total Method of Finance		
	780 G.O. Bond Proceeds	\$ 2,699,376	\$ 2,699,376

CPRIT Legislative Appropriations Request for the 2022-23 Biennium

Exceptional Item Request 2
Item Name: 8 New Grant Program, Compliance and Accounting Support

Description/Justification:	Funding for the Following Strategies	Exceptional 2022	Exceptional 2023
CPRIT requests eight (8) new full-time equivalent (FTE) positions for additional compliance/accounting and program workload demand. The request includes: -2 new Grant Accountants who will specialize in reviewing the financial reports of product development research grantees, -1 new Accountant who will primarily support grant payment processing but also provide support on general agency budget and accounting to back up the Agency Accountant, -3 new Grant Compliance Specialists to address the increasing workload of performing the necessary annual grant compliance reviews, monitoring visits, and trainings for CPRIT's portfolio of 500 active grants, -1 new Program Manager for the Academic Research Program to address the increasing programmatic workload in RFA development, tracking grant reporting documentation, data collection and analysis, and summarization of grant results, and -1 new Program Manager for the Product Development Research Program to address the increasing workload in reviewing and evaluating grant progress, monitoring the grant portfolio project metrics, data collection and analysis, summarization of grant results, and program outreach efforts across the state.	A.1.1. Award Cancer Research Grants	\$ (550,005)	\$ (534,266)
	A.1.2. Award Cancer Prevention Grants	\$ (61,112)	\$ (59,363)
	A.1.3. Grant Review and Award Operations	\$ 581,117	\$ 563,629
	B.1.1. Indirect Administration	\$ 30,000	\$ 30,000
	Total Method of Finance		
	780 G.O. Bond Proceeds	\$ 611,117	\$ 593,629



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Tab 2,
Return to Agenda

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: JAMES WILLSON, M.D., CPRIT CHIEF SCIENTIFIC OFFICER
SUBJECT: ACADEMIC RESEARCH PROGRAM FY2021 PROPOSED RFAS
DATE: JULY 31, 2020

Proposed Academic Research RFAs for Fiscal Year 21.2

The Academic Research Program proposes the following RFAs and schedule for FY21.2:

- **Core Facility Support Awards (RFA R-21.2 CFSA)**
Solicits applications from institutions of higher learning to establish or enhance core facilities (laboratory, clinical, population-based, or computer-based) that will directly support cancer research programs to advance knowledge of the causes, prevention, and/or treatment of cancer or improve quality of life for patients with and survivors of cancer.
Award: Up to \$4,000,000 (total costs); Maximum duration: 5 years.
- **High Impact/High Risk Research Awards (RFA R-21.2 HIHR)**
Provides short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers.
Award: Up to \$250,000 (total costs); Maximum duration: 2 years.
- **Early Clinical Investigator Award (ECI R-21.2 ECI)**
Solicits applications from institutions of higher learning to provide cancer physicians early in their academic career the opportunity to develop clinical research skills and to gain experience in advanced methods and experimental approaches needed to become clinical investigators. The award will protect time from clinical responsibilities to allow the early clinical investigator to develop and conduct investigator initiated clinical trials and to establish a partnership with a laboratory-based collaborator in order to design and conduct correlative studies needed to interpret the outcome of an interventional trial. The overall goal of this mechanism is to increase the pool of clinical investigators at Texas academic institutions who are conducting patient-oriented studies that capitalize on basic discoveries and translating them through conduct of innovative clinical trials involving cancer patients or individuals at risk for cancer.
Award: Up to \$1,500,000 (total costs); Maximum duration: 5 years

- **Clinical Trials Network Award (RFA R-21.2 CTNA)**

The Clinical Trials Network Award (CTNA) will be made to Lead Institutions (LI) to develop and oversee a network of two cancer care facilities (Network Affiliates), (Stage 1) to extend access to a select group of LI cancer clinical trials. Once an initial network is satisfactorily demonstrated, the LI will be eligible to receive additional CPRIT funding to expand its network to two additional facilities that must be located outside the LI current catchment (Stage 2). Institutions, organizations, or other entities (including physician groups) that conduct clinical research are eligible to be a LI or Network Affiliate.
Award: Up to \$600,000 annually for stage 1 and up to \$900,000, annually for stage 2.
Maximum duration: 4 years

- **Texas Clinical Trials Participation Program Award (RFA R-21.2 TCTPA)**

Solicits applications from institutions, organizations, or other entities (including physician groups) that conduct clinical research to establish programs to increase the number and diversity of subjects participating in therapeutic cancer clinical trials in Texas by removing nonclinical out of pocket costs as barriers to participation in cancer clinical trials for financially burdened subjects.
Award: Up to \$1,500,000 (total costs); Maximum duration: 3 years.

- **Texas Regional Excellence in Cancer Award (RFA R-21.2 TREC)**

Solicits applications to strengthen cancer research at institutions of higher learning located in regions of Texas that have historically received low levels of peer reviewed cancer research funding. Eligibility is limited to Texas institutions located > 100 mi from an NCI Designated Cancer Center. This award will support:

 - Established investigator to lead a program with a cohesive theme relevant to the cancer problems of the region
 - 3 to 5 research projects (the majority must be led by junior faculty)
 - Recruitment of new junior faculty
 - Shared resources
 - Partnerships with established Texas cancer research programs to provide mentorship and access to facilities and/or expertise

Award: Up to \$6,000,000 (total costs); Maximum duration: 5 years.

Academic Research Program RFA Timelines – FY21.2

RFA Timeline	
Post RFAs to CPRITs Application Receipt System (CARS)	August 3, 2020
Open CARS (application receipt begins)	September 16, 2020
Close CARS (application receipt ends)	January 27, 2021
Peer Review	May 20 – 27, 2021
Program Integration Committee	August 3, 2021
Oversight Committee	August 18, 2021

Note: Copies of the proposed RFAs have been uploaded to the Oversight Committee Data Room [website](#).

To access the materials, follow these steps after you have logged onto the website:

- Click on the folder “Oversight Committee Data Room”
- Click on the folder “Oversight Committee Meeting Materials”
- Click on the folder “FY2020 Meetings”
- Click on the folder “July 31,2020 Meeting”



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Tab 3,
Return to Agenda

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: CINDY WALKERPEACH, PHD
CHIEF PRODUCT DEVELOPMENT OFFICER
SUBJECT: PRODUCT DEVELOPMENT PROGRAM CYCLE 21.1 RFAS
DATE: 22 JULY 2020

Product Development Program Cycle 21.1 RFAs:

Product Development Research FY 2021 Cycle 1

Dr. WalkerPeach presented, and the Oversight Committee approved, the following three (3) RFAs during the February 2020 OC meeting:

- *Texas Company Product Development Research Award (TXCO):*
This award mechanism seeks to support early-stage “startup” and established companies in the development of innovative products and services with significant potential impact on cancer patient care. The proposed project must further the development of new products or services for the diagnosis, treatment, or prevention of cancer; must foster a robust biotechnology industry ecosystem; or must fulfill a critical unmet need in cancer patient care. Companies must be headquartered in Texas.

Strong candidates for the TXCO award have developed a sufficiently robust data package, value proposition, regulatory strategy, manufacturing plan, and experienced business management team to warrant the amount of funding requested.

Award: Up to \$20 million over a maximum timeline of three years.

- *Company Relocation Product Development Award (RELCO):*
This award mechanism seeks to support early-stage “startup” and established companies in the development of innovative products and services with significant potential impact on cancer patient care. The proposed project must further the development of new products or services for the diagnosis, treatment, or prevention of cancer; must foster a robust biotechnology industry ecosystem; or must fulfill a critical unmet need in cancer patient care. Companies must relocate to Texas within one year of receipt of award.

Strong candidates for the RELCO award have developed a sufficiently robust data package, value proposition, regulatory strategy, manufacturing plan, and experienced business management team to warrant the amount of funding requested.

Award: Up to \$20 million over a maximum timeline of three years.

- *Seed Award for Product Development Research (SEED):*
This award mechanism seeks to support early-stage “startup” companies in the development of innovative products and services with significant potential impact on cancer patient care.

The proposed project must further the development of new products or services for the diagnosis, treatment, or prevention of cancer; must foster a robust biotechnology industry ecosystem; or must fulfill a critical unmet need in cancer patient care. Company applicants must be headquartered in Texas or relocate to Texas within one year of receipt of award.

Strong candidates for the SEED award have developed compelling discovery stage data and/or developed a working prototype (if applicable), around a novel compound, diagnostic, device, computational tool, etc. that warrants further development efforts to establish proof of concept (POC) on the early pathway to commercial product. In addition, strong candidates have at a minimum developed a strong value proposition, preliminary regulatory strategy, preliminary manufacturing plan, and early business management team to warrant the amount of funding requested.

Award: Up to \$3 million over a maximum timeline of three years.

The application portal for Product Development Program Cycle 21.1 is anticipated to open December 2, 2020 and close for new application on January 27, 2021. We anticipate Cycle 21.1 award recommendations will be presented during the August 2021 OC Meeting.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: RAMONA MAGID, CHIEF PREVENTION OFFICER
SUBJECT: PREVENTION PROGRAM FY 2021 RFAS
DATE: JULY 31, 2020

Prevention Program FY 2021 Requests for Application (RFAs)

The Oversight Committee approved the four RFAs for fiscal year 2021 listed below at the May 2020 meeting. The CPRIT Prevention Program plans to have two RFA release cycles in 2021. Cycle 21.1 will include one RFA, Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations (EPS), that will be released on August 3. Cycle 21.2 will include all four previously approved mechanisms; these RFAs will be released in February 2021. The timeline for both cycles is presented in the table.

FY 2021 Prevention Program RFAs

- *Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations*
Seeks to support coordination and expansion of evidence-based services to prevent cancer in underserved populations who do not have adequate access to cancer prevention interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community and use evidence-based models shown to work in similar communities to prevent and control these cancers. Currently funded CPRIT projects should propose to expand their programs to include additional types of prevention clinical services and/or an expansion of current clinical services into additional counties in the initial expansion. This expansion must include delivery of services to nonmetropolitan and medically underserved counties in the state. Any additional expansions are not required to further expand services or geographic area but should substantially increase the number of clinical services delivered.

Initial Expansion Award: Maximum of \$2M over 36 months.

Additional Expansion Award: Maximum of \$2.5M over 60 months.

- *Evidence-Based Cancer Prevention Services*
Seeks projects that will deliver evidence-based cancer prevention and control clinical

services. CPRIT will give priority to projects that propose to address CPRIT areas of emphasis and serve areas of the state not well addressed by current CPRIT funded projects.

Award: Maximum of \$1M over 36 months.

- Tobacco Control and Lung Cancer Screening*
 Seeks programs on tobacco prevention and cessation, as well as screening for early detection of lung cancer. Through release of this RFA, CPRIT’s goal is to stimulate more programs across the state, thereby providing greater access for underserved populations and reducing the incidence and mortality rates of tobacco-related cancers. This RFA seeks to promote and deliver evidence-based programming designed to significantly increase tobacco cessation among adults and/or prevent tobacco use by youth.

Initial Award: Maximum of \$1M over 36 months.

Expansion Award: Maximum of \$2M over 36 months.

- Dissemination of CPRIT-Funded Cancer Control Interventions*
 Seeks to fund projects that will facilitate the dissemination and implementation of successful CPRIT-funded, evidence-based cancer prevention and control interventions across Texas. The proposed project should be able to develop one or more "products" based on the results of the CPRIT-funded intervention. The proposed project should also identify and assist others to prepare to implement the intervention and/or prepare for grant funding.

Award: Maximum of \$300,000 over 36 months.

Prevention Program RFA Timelines – FY 2021

Mechanism	Cycle 21.1 (EPS)	Cycle 21.2
Submission	Oct. 5, 2020	Feb. 10, 2021
Peer Review	Jan. 20-21, 2021	Apr. 26-29, 2021
Prevention Review Council	Mar. 3, 2021	Jun. 14, 2021
Program Integration Committee	May 4, 2021	Aug. 3, 2021
Oversight Committee	May 19, 2021	Aug. 18, 2021



MEMORANDUM

TO: OVERSIGHT COMMITTEE
FROM: WAYNE ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: FY 2022 PROGRAM PRIORITIES & CPRIT 2.0 PLANNING
DATE: JULY 22, 2020

Attached is a revised project timeline for development of the FY 2022 Program Priorities and the CPRIT 2.0 plan. This item is informational only; the Oversight Committee will not take action on this item at the July 31 special meeting.

Both projects were underway when the COVID-19 pandemic disrupted regular work, ended most face-to-face meetings, and cancelled all associated travel. Two product development regional meetings had occurred in San Antonio and El Paso before CPRIT suspended all staff travel. In addition, the University Advisory Committee, the Prevention Advisory Committee, the Clinical Trials Advisory Committee, the Childhood Cancer Advisory Committee, and Product Development Advisory Committees each presented recommendations to the Oversight Committee via videoconference at the May open meeting.

The 2022 Program Priorities remain on schedule for adoption at the upcoming November 18 Oversight Committee meeting. Approving the FY 2022 priorities in November allows enough time for the program staff to reflect the priorities in upcoming requests for applications. CPRIT Program Staff will discuss the 2022 priority proposals with the program subcommittees and the full Oversight Committee in August, which will allow time for refining the proposed priorities before final approval in November.

While staff proposes to resume the outreach to solicit public and state leadership input into programmatic plans for CPRIT 2.0, there are some continuing issues that may impact critical parts of the CPRIT 2.0 planning process. Meaningful input from regional stakeholders remains a challenge during the continuing COVID-19 pandemic, even if CPRIT uses videoconferencing technology to replace in person meetings. Activities related to the upcoming legislative session will also require substantial time and attention of CPRIT staff and many grantee entities as the state grapples with the impact of COVID-19 and the oil and gas revenue contraction on the FY 2022 -2023 budget. We anticipate that the Oversight Committee may adopt the initial CPRIT 2.0 plan as early as May, but the schedule will continue to evolve as CPRIT addresses the impact of issues beyond our control.



Timeline for FY 2022 Program Priorities and Development of “CPRIT 2.0” Plan *Revised July 2020*

✓June – November 2019

Initial discussions with legislators, state leadership, stakeholders, and others about CPRIT 2.0, identifying potential opportunities for CPRIT’s second decade (listed at the end of this timeline.)

✓January

Senior staff and program managers drafted development timeline for Oversight Committee review at February subcommittees and the February 19 Oversight Committee meeting.

✓Early February

CPRIT program staff prepared summaries of where CPRIT has invested grant funds over the past 10 years for each priority and by mechanism. This information was made available at the February 19 Oversight Committee meeting.

✓February Subcommittees and February 19 Oversight Committee Meeting

Staff introduced initial formal timeline and process for creating the CPRIT 2.0 plan and 2022 Program Priorities to Oversight Committee subcommittees and the public at February 19 Oversight Committee meeting.

✓March/April

Advisory committees met in March and April to develop suggestions for CPRIT 2.0 and 2022 Program Priorities; the Advisory Committees presented their suggestions at the May 20 Oversight Committee meeting.

✓(partial) Spring/Summer

Program Chiefs sought external input from stakeholders through scheduled meetings and informal venues. CPRIT suspended plans to initiate public forums seeking input at sites across the state. Outreach activities accomplished include:

- Discussion and input from all CPRIT advisory committees.
- Regional meetings in San Antonio and El Paso provided input related to the Product Development Research Program .
- CPRIT staff discussed preliminary partnership opportunities with entities including Susan G. Komen Foundation, the Prostate Cancer Foundation and the Lyda Hill Foundation.

✓May 20 Oversight Committee Meeting

CPRIT’s four advisory committees presented their annual reports to the Oversight Committee, including preliminary advice and recommendations about CPRIT 2.0 and 2022 Program Priorities.

2022 Program Priorities

The Oversight Committee establishes program priorities more than 12 months in advance of the applicable fiscal year to allow CPRIT programs enough time to develop requests for applications that incorporate the priorities. The fiscal year 2022 priorities will be the first program priorities that will guide the award of the funds approved by voters in November 2019.

July 31

Staff presents revised “Timeline for Development of 2022 Program Priorities and CPRIT 2.0 Plan” to the Oversight Committee for review and discussion.

August

Staff prepares draft 2022 Program Priorities for discussion at Oversight Committee subcommittees and the August 19 Oversight Committee meeting.

September/October

Additional Oversight Committee subcommittee meetings scheduled as necessary to discuss 2022 Program Priorities.

October/Early November

Staff prepares final draft of 2022 Program Priorities for review by Oversight Committee subcommittees in preparation for the November 18 Oversight Committee meeting.

November 18

Oversight Committee receives public input on 2022 Program Priorities and approves the final 2022 priorities.

CPRIT 2.0 Planning

July-October

Staff develops a draft schedule to engage the public, state leadership and the Oversight Committee in CPRIT 2.0 planning. Staff drafts preliminary CPRIT 2.0 concept ideas to facilitate stakeholder discussions.

November

Staff updates the Oversight Committee subcommittees on CPRIT 2.0 activities and schedule changes/additions (if any) in preparation for the November 18 Oversight Committee meeting.

November 18

Oversight Committee discusses the CPRIT 2.0 activities, process, and schedule changes or additions and provides staff direction on proceeding.

December 2020 – May 2021

Outreach activities and solicitation of stakeholder input continues. Additional discussion, planning and development of a draft CPRIT 2.0 Plan document for possible approval at May 2021 Oversight Committee meeting.

During discussions in 2019 about increasing the state's investment in cancer research and prevention with legislators, state leadership, and stakeholders, CPRIT identified several potential ideas, listed below, as a preliminary framework for CPRIT 2.0.

- Capitalizing on CPRIT's longstanding investments in improving outcomes in childhood cancer; with continued support, Texas can be the world leader in childhood cancer research
- Grow and enhance the coalitions and networks delivering cancer prevention services by providing infrastructure to support them
- Creating and expanding research and treatment capabilities at universities in all regions of the state
- Boosting clinical trial options to more people by reducing the institutional and patient barriers to trials
- Increasing the number and breadth of Collaborative Action Programs (CAPs) that target Texas-centric needs in cancer research and prevention. The CPRIT-initiated liver cancer CAP is addressing liver cancer, which Texas ranks first among states in incidence rate
- Taking advantage of the pipeline of novel cancer diagnostic and treatment discoveries at Texas universities by supporting the transition of early stage development in the growing number of Texas-based companies
- Doubling the number of NCI Comprehensive Cancer Centers and elevate Texas institutions' standing in prominent national reviews such as the *US News and World Report's* rankings through continued investment in research capacity, access to cutting-edge technology, and recruiting preeminent experts and the next generation of scientific leaders to Texas
- Co-investing with established bio-tech venture capital firms in promising Texas-based companies, sharing the risks and rewards equally



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

[Tab 6,
Return to Agenda](#)

MEMORANDUM

TO: OVERSIGHT COMMITTEE
FROM: WAYNE ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: FUTURE MEETING DATES AND AGENDA ITEMS
DATE: JULY 22, 2020

The next regular quarterly Oversight Committee is 9:00 a.m. August 19, 2020.

Since the August meeting will be the last meeting of FY 2020, the Oversight Committee will have a full agenda with many critical action items. In addition to our regular agenda items and the many awards for each program, there will be significant items requiring the Oversight Committee's consideration and action, including the FY 2021 honoraria policy, the FY 2021 conflict of interest waivers, audit reviews and large contract approvals.

Based on our experience, CPRIT staff expects the August meeting to last four – five hours. Please allow sufficient time before the meeting to review all the award materials and complete the conflict of interest information via the CPRIT award portal. To make sure that CPRIT's IT staff can address any technical issues Oversight Committee members may have without delaying the start of the meeting, plan to log in to the August 19 meeting at least 30 minutes early.

